Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation (UPSAT)

2 juin 2022 mis à jour par: Johns Hopkins University

UPright Incline Positioning in COVID-19 Patients for Oxygen SATuration Improvement With Hypoxemic Respiratory Failure (UPSAT)

COVID-19 is a respiratory illness caused by SARS-CoV-2 with a range of symptoms from mild, self-limiting respiratory tract infections to severe progressive pneumonia, multiorgan dysfunction and death. A portion of individuals with COVID-19 experience life-threatening hypoxia requiring supplemental oxygen and mechanical ventilation. Management of hypoxia in this population is complicated by contraindication of non-invasive ventilation and limitations in access to mechanical ventilation and critical care staff given the clinical burden of disease. Positional therapy is readily deployable and may ultimately be used to treat COVID-19 related respiratory failure in resources limited settings; and, it has been demonstrated to improve oxygenation and is easy to implement in the clinical setting.

The overall goal of this randomized controlled trial is to establish the feasibility of performing a randomized trial using a simple, minimally invasive positional therapy approach to improve hypoxia and reduce progression to mechanical ventilation. The objectives are to examine the effectiveness and feasibility of maintaining an inclined position in patients with confirmed or suspected COVID-19 associated hypoxemic respiratory failure. The investigators hypothesize that (1) oxyhemoglobin saturation will improve with therapy, (2) participants will tolerate and adhere to the intervention, and that (3) participants who adhere to positional therapy will have reduced rates of mechanical ventilation at 72 hours. If successful, this feasibility trial will demonstrate that a simple, readily deployed nocturnal postural maneuver is well tolerated and reverses underlying defects in ventilation and oxygenation due to COVID-19. It will also inform the design of a pivotal Phase III trial with estimates of sample sizes for clinically relevant outcomes.

Aperçu de l'étude

Statut

Résilié

Intervention / Traitement

Description détaillée

Study Design: The investigators will conduct a pilot study to examine the acute effects of inclined posture on oxyhemoglobin saturation and the feasibility of conducting randomized controlled clinical trial among patients with confirmed or suspected COVID-19-associated hypoxia.

In a subgroup of participants, the investigators will examine the acute effect of postural therapy (15-degree incline on hospital beds) on oxyhemoglobin saturation among hypoxic patients to establish a biologic response. The investigators will enroll a subset of participants (n=16) who will lie supine on hospital beds, which will be placed in the horizontal (flat) or 15-degree inclined (reverse Trendelenberg) orientation in random order. During this time, the investigators will continuous record pulse oximetry, pulse rate and variations in peripheral arterial tone with WatchPAT one devices. Subjects will be visually monitored for work of breathing during this time. If work of breathing becomes excessive, as defined as a sustain respiratory rate of >25 and an increase of >5 breaths per minute from baseline, or oxygenation decreases below 88% for > 30 seconds in the inclined position, then maneuvers will be stopped. If the patient meets these criteria in the flat position, then the investigators sit the patient upright, and allow breathing to return to baseline before examining responses in the inclined position.

The investigators will randomize participants to have beds placed in 15-degree incline or usual care (ad-lib positioning) for 72 hours. During the first night in a subgroup of participants, the investigators will record oxygenation, sleep wake state and markers of sympathetic activity with WatchPAT One devices, which can obtain cardiopulmonary parameters with high temporal resolution. The investigators will obtain vital signs from the data warehouse, which archives telemetry data with a maximum sampling frequency of 1 minute. The investigators will record adherence with continuous accelerometry sensors placed on the bed rails and on the anterolateral surface of participants' chests to measure bed and participants' positions, respectively. Aside from position, participants will receive usual treatment for COVID-19.

The investigators will enroll in 3 phases. At the end of each phase, the investigators will assess for completion of milestones for proceeding to the subsequent phase, as detailed below:

  1. Pilot Study: The investigators will pilot the study in 16 participants to obtain critical information on logistics of conducting the trial including performance of recording instruments in a biocontainment environment, to examine the feasibility of the intervention, perform preliminary safety evaluations to ascertain potential harm and to determine whether the intervention results in a meaningful difference in body position.
  2. Phase II RCT: If inclined therapy results in a difference in body position and no significant safety issues were detected, the investigators will conduct a phase II randomized-controlled trial (RCT) in 70 participants (see sample size calculation below) to estimate the effect size of inclined position on rates of intubation and determine sample size for a Phase III trial.

Randomization will be occur in both phases and will be stratified by study phase and study site.

Type d'étude

Interventionnel

Inscription (Réel)

7

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Maryland
      • Baltimore, Maryland, États-Unis, 21287
        • Johns Hopkins Hospital
      • Baltimore, Maryland, États-Unis, 21224
        • Johns Hopkins Bayview Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • COVID-19 positive
  • Pneumonia defined as hospitalization for acute (< 7 days) onset of symptoms (cough, sputum production, or dyspnea).
  • Hypoxemia defined as ≥ 2 L/min oxygen

Exclusion Criteria:

  • Intubation
  • Inability to lie supine

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Postural Positioning
Participants in the group will have hospital beds placed in 15 degree (reverse Trendelenburg).
Investigators will adjust the positioning of hospital beds to assess improvements in oxygenation and respiratory status.
Aucune intervention: Standard Care
Participants in this group will have beds managed per standard nursing protocol.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Incidence of Mechanical Ventilation
Délai: 72 hours
Number of participants needing mechanical ventilation over total number of participants per arm.
72 hours

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Number of participants with supplemental oxygen requirements
Délai: 72 hours
Number of participants with supplemental oxygen requirements.
72 hours
Mean oxyhemoglobin saturation
Délai: At 24, 48 and 72 hours
Mean oxyhemoglobin saturation (percentage) measured over a 24-hour period.
At 24, 48 and 72 hours
Mean Nocturnal Oxyhemoglobin Saturation
Délai: Measured between 10pm and 6am daily, up to 72 hours
Mean oxyhemoglobin saturation (percentage) measured over an 8-hour period (between 10pm and 6am).
Measured between 10pm and 6am daily, up to 72 hours
Heart Rate
Délai: At 10, 24, 48 and 72 hours
Heart Rate (beats per minute) on Routine Vital Sign Assessment.
At 10, 24, 48 and 72 hours
Respiratory Rate
Délai: At 10, 24, 48 and 72 hours
Respiratory Rate (cycles per minute) on Routine Vital Sign Assessment.
At 10, 24, 48 and 72 hours
Percentage of time in the assigned position
Délai: 72 hours
Percentage of time participants stay in the assigned position will be used to determine adherence.
72 hours

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Acute change in oxyhemoglobin saturation
Délai: During the final 7 minutes at each position, up to 72 hours
Mean oxyhemoglobin saturation (percentage) during final 7 minutes in a position.
During the final 7 minutes at each position, up to 72 hours

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Luu Pham, MD, Johns Hopkins University

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

25 mai 2020

Achèvement primaire (Réel)

1 mai 2022

Achèvement de l'étude (Réel)

1 mai 2022

Dates d'inscription aux études

Première soumission

10 avril 2020

Première soumission répondant aux critères de contrôle qualité

10 avril 2020

Première publication (Réel)

14 avril 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 juin 2022

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 juin 2022

Dernière vérification

1 juin 2022

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • IRB00246834

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Access to IPD on reasonable request

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner